Presbyopia Treatment Market Size & Outlook, 2025-2033

Presbyopia Treatment Market Size

The global presbyopia treatment market size was valued at USD 10.17 billion in 2024 and is projected to grow from USD 10.73 billion in 2025 to reach USD 16.47 billion in 2033, growing at a CAGR of 5.5% during the forecast period (2025–2033).

The market is experiencing significant growth, driven by the rising geriatric population with eye-related issues, increasing screen time, and heightened awareness about presbyopia treatment options. Presbyopia, a condition that affects near vision, can be managed through various ophthalmic and surgical treatments. The main treatment modalities include glasses, such as reading glasses or bifocals/progressive lenses, and contact lenses, which can be multifocal or monovision lenses.

In addition to these, surgical procedures and minimally invasive therapies are gaining popularity as effective treatment options. The growing demand for eye care services, the increasing prevalence of digital eye strain, and ongoing R&D efforts focused on novel solutions are further propelling market growth. Notably, the development of pharmacological treatments, such as miotics like pilocarpine, has shown promising results in improving near vision through the pinhole effect.

A systematic review published in November 2024 highlighted the progress in this area, showcasing the potential of miotics in managing presbyopia. These advancements in research and development play a crucial role in shaping the market. By improving the convenience and accessibility of treatments for patients, ongoing innovation is not only driving market growth but also enhancing the quality of life for individuals affected. As these developments continue to evolve, the market is poised for sustained expansion.

Market Trends

Growing Adoption of Premium Iols (intraocular Lenses) for Surgical Correction

The increasing demand for premium intraocular lenses (IOLs) is transforming the global market as patients seek long-term solutions beyond corrective glasses. These advanced IOLs offer improved near-, intermediate-, and distance vision, providing a comprehensive approach to vision correction.

• For instance, in August 2024, Contact Lens Anterior published a study highlighting the growing use of spectacle-independent trifocal and extended depth of focus (EDOF) IOLs. These lenses are gaining popularity due to their ability to reduce contrast loss and glare, providing patients with clearer, more natural vision across all distances.

The continuous innovation in IOL designs, customized to enhance near and intermediate vision, is reflecting the growing market trend for premium IOLs, further driving market growth.

Rise of Scleral and Corneal Inlays as Minimally Invasive Solutions for Presbyopia Correction

The demand for minimally invasive presbyopia treatments has significantly increased, leading to the development of scleral and corneal inlays as a solution. These innovative inlays restore near vision without the need for major surgery, offering patients a less invasive alternative to traditional surgical procedures.

• For instance, in December 2022, a clinical trial of the CorVision biosynthetic collagen corneal inlay (LinkoCare) demonstrated its effectiveness and biocompatibility for presbyopia correction. The trial revealed that 94% of patients were satisfied with the procedure after 12 months, and 96.5% would recommend it.

Such breakthroughs in minimally invasive solutions are reinforcing the growing preference for biocompatible and effective presbyopia treatments, making this market segment a significant area of growth.

To get more insights about this report Download Free Sample Report

Presbyopia Treatment Market Growth Factors

Increasing Prevalence of Distance Vision Impairment

The rising incidence of distance vision impairment is a key driver for the growth of the presbyopia treatment market. As more individuals experience challenges with distance vision, there is an increased demand for advanced presbyopia treatments.

• According to the World Health Organization (WHO), in August 2023, vision impairment affects at least 2.2 billion people globally, with 1 billion of these cases being preventable or treatable.

This underscores the urgent need for innovative presbyopia treatments, including surgical, non-surgical, and pharmacological solutions, accelerating the demand for market-driven therapies.

Expanding the Availability of Eye Care Services

Expanding access to eye care services is essential to addressing the growing need for presbyopia treatment, particularly in underserved and less privileged regions. Efforts to make vision care more accessible and affordable globally are catalyzing market growth.

• In response to the global vision impairment crisis, the UN General Assembly passed a resolution in 2023 to incorporate eye care services into universal health coverage. This initiative aims to reach over 2 billion individuals with vision impairments, boosting investment in early diagnosis and treatment.

As the accessibility of eye care services expands, the demand for presbyopia solutions like corneal inlays and advanced IOLs is also increasing, especially in emerging markets where such treatments were previously out of reach.

Restraining Factor

High Cost of Advanced Presbyopia Treatments

The high cost of advanced presbyopia treatments, such as corneal inlays, premium intraocular lenses (IOLs), and laser surgeries, remains a significant barrier to market growth. These treatments often come with steep price tags, making them unaffordable for many patients, particularly in low- and middle-income regions.

Limited insurance coverage for elective procedures exacerbates this issue, hindering access to these advanced solutions. Moreover, the substantial R&D costs associated with creating new drugs and surgical methods further contribute to the high prices, ultimately slowing market adoption and limiting growth potential in emerging economies.

Market Opportunity

Advancements in Pharmacological Treatments for Presbyopia

Innovative pharmacological treatments for presbyopia, which aim to address vision impairments without the need for surgery or glasses, are opening up new opportunities in the market. These treatments, such as eye drops, offer a non-invasive alternative to traditional methods.

• For instance, the U.S. Food and Drug Administration (FDA) approved VUITY, the first eye drop to treat presbyopia, using a 1.25% pilocarpine HCl ophthalmic solution. This eye drop works by improving near vision through a pinhole effect, offering a non-invasive solution to the millions affected by presbyopia.

The approval of such treatments marks the beginning of new market opportunities, offering a potential alternative to glasses and surgery, thus driving the market’s growth and diversification.

Regional Insights

North America holds a dominant position in the global presbyopia treatment market, driven by a high incidence of presbyopia, advanced healthcare infrastructure, and rapid adoption of innovative treatments. The region's strong market growth is supported by the high penetration of novel interventions such as pharmaceutical treatments and advanced surgical options.

Moreover, rising awareness, favorable reimbursement policies, and increasing demand for premium intraocular lenses (IOLs) are all key factors propelling market expansion. With a well-established healthcare system and a large aging population, North America remains a hub for presbyopia treatments, ensuring continued growth.

The U.S. market is leading, fueled by its advanced healthcare infrastructure and the growing prevalence of presbyopia. As of August 2023, the AOA Health Policy Institute reported that 128 million Americans (over 90% of adults aged 45 and older) are affected. This substantial patient base, coupled with access to advanced treatments, presents a significant opportunity for market growth in the U.S., driving demand for innovative solutions.

Asia Pacific Presbyopia Treatment Market Trends

Asia-Pacific region is projected to witness the highest CAGR, driven by the rapidly aging population, a surge in the prevalence of eye diseases, and increasing healthcare expenditures. Additionally, the growing adoption of advanced ophthalmic products, improved availability of treatments, and rising disposable incomes contribute to the market's expansion. Countries like China, Japan, and India are at the forefront, with a growing awareness of presbyopia and the increasing demand for both traditional and advanced treatment options, positioning Asia-Pacific as a dynamic and rapidly evolving market.

China market is gaining momentum due to advancements in infrastructure, research, and clinical trials. In October 2024, Corxel and Lenz Therapeutics reported successful Phase 3 trial results for LNZ100, a presbyopia eye drop formulation. The trial showed promising results, with 69% of patients experiencing significant near vision improvement. This non-invasive, reversible treatment presents a breakthrough alternative to eyeglasses, propelling the demand for advanced ophthalmic solutions in China’s growing market.

India’s presbyopia treatment industry is experiencing rapid expansion, driven by government initiatives and regulatory advancements. In September 2024, Entod Pharmaceuticals received approval from the Drug Controller General of India (DCGI) for PresVu, the first topical presbyopia treatment in the country. This approval significantly reduces the dependence on reading glasses, making India a key innovator in ophthalmic drug development and further fueling the growth of the market in the region.

Europe Presbyopia Treatment Market Trends

Germany remains a key player in Europe's market, driven by significant investments in research and government initiatives. In July 2022, the German Federal Ministry of Education and Research (BMBF) funded a groundbreaking laser eye surgery research project by SCHWIND eye-tech solutions with €1.6 million in investments. This initiative enhances treatment accessibility, expanding Germany's market for presbyopia treatment.

In France, the presbyopia treatment industry is bolstered by increasing incidences of the condition and strong government support. In January 2025, Laclarée, based in Villeurbanne, secured €3.5 million in seed funding to develop autofocusing spectacles for presbyopia, which are expected to hit the market by mid-2026. Such innovative projects, combined with governmental funding, are positioning France for significant growth in the presbyopia treatment sector, driving further market advancements.

Treatment Insights

The corrective lenses segment dominates the global market, leading in revenue due to their affordability, ease of use, and non-invasive nature. Corrective lenses, including reading glasses, bifocals, and multifocal contact lenses, are preferred for their immediate results and wide availability.

• For instance, a 2023 ESCRS Clinical Trends Survey revealed that 42% of surgeons preferred trifocal lenses for presbyopia correction, highlighting their effectiveness.

The rising adoption of second-generation intraocular lenses (IOLs) for surgical treatments further fuels the market, enhancing vision at multiple focal points and driving demand.

End-User Insights

Hospitals hold the largest market share, driven by the growing prevalence of eye conditions, advanced diagnostic tools, and skilled ophthalmologists. Hospitals are often the first point of contact for presbyopia patients, offering a comprehensive range of services, from corrective glasses to surgical and pharmaceutical treatments. The presence of state-of-the-art equipment and specialized care contributes to the growing preference for hospital-based treatments. Moreover, hospitals are pivotal in providing a seamless experience, combining diagnostic, treatment, and follow-up care to effectively manage presbyopia.

Company Market Share

Key players in the market are actively adopting strategic business initiatives such as collaborations, mergers and acquisitions, product approvals, and innovative product launches to strengthen their market presence. By forging partnerships with research institutions, investing in advanced technologies, and expanding their product portfolios, companies aim to enhance treatment efficacy and accessibility.

Allergan: An Emerging Player in the Global Presbyopia Treatment Market

Allergan, a globally recognized pharmaceutical company, specializes in eye care, aesthetics, neurosciences, and gastroenterology. It is primarily focused on developing and commercializing branded prescription drugs, biologics, and regenerative medicines. With a strong research-driven approach, Allergan has introduced innovative treatments for ophthalmic conditions, including presbyopia.

Recent Developments by Allergan:

• In October 2021, Allergan (a subsidiary of AbbVie) announced that the U.S. Food and Drug Administration (FDA) cleared VUITY (pilocarpine HCl ophthalmic solution) 1.25% presbyopia in adults, also known as blurry near vision due to age.

List of key players in Presbyopia Treatment Market

1. Ziemer Ophthalmic Systems AG
2. NIDEK CO., LTD.
3. Johnson & Johnson Vision
4. Essilor Ltd.
5. Zeiss
6. Bausch & Lomb
7. haag-streit.com
8. Allergan (AbbVie Inc.)
9. Rayner Group
10. NIDEK CO., LTD.
11. STAAR Surgical
12. Alcon Inc.
13. CooperVision
14. LENZ Therapeutics, Inc.
15. Sanofi 

To get more findings about this report Download Market Share

Recent Developments

• October 2024 – LENZ Therapeutics, Inc. stated that its New Drug Application (NDA) for LNZ100 has been accepted by the U.S. Food and Drug Administration (FDA) LNZ100: First in class aceclidine eyedrop for presbyopia-induced near vision loss.

Analyst Opinion

As per our analysts, the global presbyopia treatment market is set for substantial expansion, driven by the aging population, advancements in ophthalmic technologies, and a rising preference for non-surgical treatment options. The increasing adoption of pharmacological treatments, such as presbyopia-correcting eye drops, alongside innovations in smart glasses and adaptive contact lenses, is expected to revolutionize the market.

Despite these promising trends, the market faces challenges such as the high cost of advanced treatments, limited reimbursement coverage, and the need for long-term efficacy data for novel solutions. Moreover, regulatory hurdles and the potential side effects of emerging therapies may slow widespread adoption.

However, the expanding market in Asia-Pacific and Latin America presents significant opportunities. Growing awareness, improving healthcare infrastructure, and increasing affordability are expected to drive higher adoption rates in these regions, ultimately boosting the global market in the coming years.